Gillian Cannon Net Worth

Gillian Cannon biography

Dr. Gillian M. Cannon Ph.D. serves as Director of the Company. Dr. Cannon brings to Corcept more than 30 years experience in the pharmaceutical industry, where she has served in leadership roles at Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals. In her 27-year career at Merck, Dr. Cannon held a variety of senior positions, including Global Vice President for Commercial Operations at Merck's start-up biosimilar business, Merck BioVentures; Business Unit Head for Merck's specialty products franchise; and Global Commercial Head of its neuroscience franchise. She is currently President of Alyvant and Executive in Residence for Roivant Sciences.

What's Gillian Cannon's mailing address?

Gillian's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, Z4, V5G 4W8.

Insiders trading at Corcept Therapeutics Inc

Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson, eVentures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.

What does Corcept Therapeutics Inc do?

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis

Corcept Therapeutics Inc executives and stock owners

Corcept Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joseph Belanoff,
  President, Chief Executive Officer, Director
• Andreas Grauer,
  Chief Medical Officer
• Gary Robb,
  Chief Financial Officer, Secretary
• Sean Maduck,
  Senior Vice President - Commercial
• Dr. Joseph K. Belanoff M.D.,
  Co-Founder, Pres, CEO & Director
• Dr. Joseph K. Belanoff,
  Co-Founder, Pres, CEO & Director
• Dr. Hazel Hunt Ph.D.,
  Chief Scientific Officer
• Gary Charles Robb,
  Chief Bus. Officer & Sec.
• Sean Maduck,
  Chief Commercial Officer
• James Wilson,
  Independent Chairman of the Board
• Kimberly Park,
  Independent Director
• Daniel Swisher,
  Independent Director
• David Mahoney,
  Independent Director
• George Baker,
  Independent Director
• Gillian Cannon,
  Director
• Gregg Alton,
  Independent Director
• J.D. Lyon,
  Chief Accounting Officer
• Dr. William Guyer Pharm.D.,
  Chief Devel. Officer
• Donald E. Laferle,
  Sr. VP
• Amy Flood,
  Chief HR & Communications Officer
• Dr. Christopher Shayne James M.D.,
  Director of Investor Relations
• Joseph Douglas Lyon,
  Chief Accounting Officer
• Atabak Mokari,
  Chief Financial Officer
• Renee D Gala,
  Director
• G Leonard Jr Baker,
  Director
• Daniel Bradbury,
  Director
• Robert S Fishman,
  Chief Medical Officer
• Bakker Juliet Tammenoms,
  10% owner
• Venture Partners L.P.Longit...,
  
• Venture Partners Lp Longitu...,
  
• Steven Lo,
  VP Commercial Operations
• Biopharma Partners Ii Lpalt...,
  
• Allen Andersson,
  Director
• Ventures, Llc Paperboy,
  10% owner
• Edward Penhoet,
  Director
• Patrick G Enright,
  Director
• Caroline M Loewy,
  Chief Financial Officer
• Venture Partners Lp Longitu...,
  
• Hill Ventures Sutter,
  10% owner
• Biopharma Partners Ii Lpmar...,
  
• Biopharma Partners Ii Lpalt...,
  
• Alix Marduel,
  Director
• Alan F Schatzberg,
  Director
• David B Singer,
  Director
• Fred Kurland,
  Chief Financial Officer
• Joseph L Turner,
  Director
• Anne M Le Doux,
  VP & Controller
• Joseph C Jr Cook,
  Director
• William H Jr Younger,
  10% owner
• Robert L Roe,
  President and Secretary
• Hill Venturesbaker G Leonar...,
  Director
• Jeffrey W Bird,
  10% owner
• Tench Coxe,
  10% owner
• James N White,
  10% owner
• Gregory P Sands,
  10% owner
• Hill Venturesbaker G Leonar...,
  Director
• David L Anderson,
  10% owner
• Hill Ventureswhite James N ...,
  
• Michael L Speiser,
  10% owner
• James C Gaither,
  10% owner
• David E Sweet,
  10% owner
• Hill Venturesbird Jeffrey W...,
  
• James A Harper,
  Director
• Joshua M. Murray,
  
• Atabak Mokari,
  Chief Financial Officer
• William Guyer,
  Chief Development Officer
• Hazel Hunt,
  Chief Scientific Officer